AIPT - Precision Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6800
-0.0100 (-1.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.6900
Open0.7000
Bid0.00 x 1200
Ask1.18 x 800
Day's Range0.6790 - 0.7000
52 Week Range0.6500 - 1.5800
Volume10,394
Avg. Volume71,193
Market Cap8.834M
Beta (3Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire28 days ago

    Precision Therapeutics Reports Third Quarter 2018 Financial Results

    MINNEAPOLIS, Nov. 14, 2018 -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized.

  • GlobeNewswire28 days ago

    Helomics Corp Partners with UK 100,000 Genomes Project to Drive its Artificial Intelligence-Powered Precision Oncology Platform for Ovarian Cancer

    Helomics will utilize whole genome and outcome data from the U.K. 100,000 Genomes Project to advance its artificial intelligence-based platform for ovarian cancer. PITTSBURGH and LONDON, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Helomics, a personalized healthcare company whose mission is to improve the standard of care for cancer through innovative precision oncology products and boutique CRO services, and Genomics England announced today that Helomics has become a full Discovery Forum partner. Helomics will utilize the rich de-identified genomics and clinical data set for the 100,000 Genomes Project to further develop its artificial intelligence-based precision oncology platform for ovarian cancer.

  • GlobeNewswirelast month

    Precision Therapeutics to Hold Business Update Conference Call on November 14, 2018

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the fiscal third quarter of 2018 on November 14, 2018 after U.S. markets close. To access the conference call, U.S.-based listeners should dial +1 800-239-9838 and international listeners should dial +1 323-794-2551. Precision Therapeutics (AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.

  • GlobeNewswirelast month

    Precision Therapeutics Secures Rights to Novel Technology Designed To Develop Drugs That Target Specific Cancer by Its Mutation

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has acquired rights to technology for the proprietary culture media to grow ovarian cancer cell types in the laboratory for research and testing. TumorGenesis, Inc. (“TumorGenesis”), a wholly owned subsidiary of Precision, has developed a discovery kit using this technology for screening of these ovarian cancer cell types. This effort is part of the partnership of TumorGenesis and GLG to advance ovarian cell capture, culture and chemistry (screening multiple oncology compounds against a patient’s individual tumor).

  • GlobeNewswirelast month

    Precision Therapeutics’ CEO Talks with Uptick Newswire’s Stock Day Podcast About Exciting New Breakthroughs in Tumor Treatment and What’s on the Horizon

    Precision Therapeutics (Nasdaq: AIPT) (The “Company”) is a company applying artificial intelligence to personalized medicine and drug discovery. “It’s been almost 4 months of steady work on this merger,” explained Schwartz.

  • GlobeNewswirelast month

    Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has filed a Form S-4 registration statement with the Securities and Exchange Commission (“SEC”) regarding its proposed merger transaction with Helomics Holding Corporation (“Helomics”), and has also filed a Current Report on Form 8-K regarding the Form S-4 filing. To be added to the Precision Therapeutics’ database, please email Info@MoneyInfo-llc.com with your email address.  This is solely for the use of Precision Therapeutics and will not be sold or distributed to third parties.

  • GlobeNewswire2 months ago

    Precision Therapeutics’ Skyline Medical Division Signs International Distribution Agreement with India-based Prenit World

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) is pleased to announce that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has partnered with Prenit World, an international distributor of medical infrastructure solutions for healthcare facilities, to market the STREAMWAY System in India. Signing this international distribution agreement represents the Company’s entry into India’s bourgeoning healthcare market.

  • GlobeNewswire2 months ago

    Precision Therapeutics Secures First STREAMWAY System Sale in Europe

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) is pleased to announce it has secured its first European sale of the STREAMWAY System®, an automated, direct-to-drain medical fluid disposal system sold by the Company’s Skyline Medical division. The European Union has approximately 15,000 hospitals and is experiencing an increasing push toward improved healthcare waste management, representing a major new market for the Company. The Company established its European expansion strategy in early 2018, with the opening of new European headquarters and the hiring of a cross-continent team, led by a new Vice President of International Sales in Belgium and supported by a Director of Sales in Germany, among other sales representatives.

  • GlobeNewswire3 months ago

    Dr. Bob Murphy, Head of Computational Biology at Carnegie Mellon University, Joins Precision Therapeutics’ Scientific Advisory Board

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Robert Murphy to its Scientific Advisory Board. Dr. Murphy is the Ray and Stephanie Lane Professor of Computational Biology and Head of the Computational Biology Department in the School of Computer Science at Carnegie Mellon University.

  • GlobeNewswire3 months ago

    Precision Therapeutics Bolsters Scientific Advisory Board with the Appointment of Dr. Paul Kornblith

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has bolstered its Scientific Advisory Board with the appointment of Dr. Paul Kornblith, founder and former Chairman and CEO of Helomics Corporation. The Scientific Advisory Board was formed by Precision Therapeutics in September 2018, with Dr. Marc Malandro and Dr. Amelia Warner appointed shortly thereafter.

  • ACCESSWIRE4 months ago

    Skyline Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Skyline Medical, Inc. (NASDAQ: AIPT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE5 months ago

    Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies

    EAGAN, MN / ACCESSWIRE / July 17, 2018 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (AIPT). As Dr. Schwartz told CEOCFO's Bud Wayne, Precision Therapeutics has become a leader in personalized treatments for cancer both through its own efforts and though its recent merger with Helomics. "Precision Therapeutics is a unique entity, with a very bright future," said Dr. Schwartz.